Market Highlights
HIV drugs aim to control the growth of the human immunodeficiency virus (HIV), improve the patient’s overall immune system, and reduce/stop the symptoms. The drugs used to treat HIV infection are antiretrovirals, which help reduce the viral load and fight the infection.
The growth of the global HIV drug market is driven by the increasing prevalence of HIV infection, rising awareness of HIV treatment, and the launch of innovative drugs. However, stringent regulatory policies for drug approval and product recalls are expected to curb the growth of the global HIV drug market during the assessment period.
According to MRFR analysis, HIV Drugs Market size is expected to register a CAGR of 5% during the forecast period of 2019 to 2025 and was valued at USD 24 million in 2018.
The global HIV drugs market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.
Segmentation
The global HIV drug market has been segmented based on type and end-user. The market, based on type, has been divided into nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, integrase inhibitors, post-attachment inhibitors, and pharmacokinetic enhancers.
The drugs in these different segments differ with respect to their mechanism of treating the HIV infection. The different approaches for treatment are, inhibiting HIV’s reverse transcriptase, preventing HIV maturation, and preventing the entry of the virus into the host cells, among others.
The global HIV drugs market has been segmented based on end-user, into hospitals & clinics, specialty centers, and others. The hospitals & clinics segment is expected to hold the largest market share due to an increasing number of hospitals.
